Estrella Immunopharma, Inc. (ESLA) Stock Ticker
ESLA right now
Market factors today
Unlock the full ESLA picture
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
ESLA stock facts
| Ticker symbol | ESLA |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $20.5M |
| CEO | Cheng Liu |
| Employees | 3 |
| Headquarters | EmeryVille, CA, US |
| IPO date | 2021-09-14 |
| Website | www.estrellabio.com |
What you can see for ESLA on Tickr
Live ESLA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ESLA report.
Rankings
FAQ
What is the ticker symbol for Estrella Immunopharma, Inc.?
The ticker symbol for Estrella Immunopharma, Inc. is ESLA, listed on the NASDAQ Capital Market.
What is ESLA?
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse…